![Paul van Hagen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul van Hagen worked as a Senior Director of Finance & Control at Prosensa Holding NV, a Senior Manager at Ernst & Young Nederland LLP, and as a Chief Financial Officer at Xeltis AG.
He also served as Vice President of Finance at Kiadis Pharma NV from 2018 to 2019.
He completed his undergraduate degree at the University of Groningen.
| Sociétés | Poste | Fin |
|---|---|---|
Ernst & Young Nederland LLP (Netherlands)
 Ernst & Young Nederland LLP (Netherlands) Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Corporate Officer/Principal | - |
Xeltis AG
 Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery | Directeur Financier/CFO | - |
| KIADIS PHARMA N.V. | Directeur Financier/CFO | - |
| PROSENSA HOLDING NV | Directeur Financier/CFO | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
University of Groningen
 University of Groningen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ernst & Young Nederland LLP (Netherlands)
Ernst & Young Nederland LLP (Netherlands) Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Engages in the development of ribonucleic acid-modulating or RNA-modulating, therapeutics for the treatment of genetic disorders | Health Technology |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery | Health Technology |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company focused on research, development and commercialization of cell based immunotherapy products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
